

Medibio Limited
Appendix 4D
Half-year report

1. Company details

Name of entity: Medibio Limited
ABN: 58 008 130 336
Reporting period: For the half-year ended 31 December 2022
Previous period: For the half-year ended 31 December 2021

2. Results for announcement to the market

| | | | \$ |
|---|------|----------|-----------|
| Revenues from ordinary activities | down | 1.8% to | 961,025 |
| Loss from ordinary activities after tax attributable to the owners of Medibio Limited | down | 34.7% to | (420,700) |
| Loss for the half-year attributable to the owners of Medibio Limited | down | 34.7% to | (420,700) |

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the group after providing for income tax amounted to \$420,700 (31 December 2021: \$644,694).

3. Net tangible assets

| | Reporting period Cents | Previous period Cents |
|---|------------------------------|-----------------------------|
| Net tangible assets per ordinary security | <u>(0.016)</u> | <u>(0.006)</u> |

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

12. Signed



Signed _____

Date: 24 February 2023

David Trimboli, Non-Executive Chair

Medibio Limited
Corporate directory
31 December 2022

| | |
|-------------------------|---|
| Directors | Mr David Trimboli (Non-Executive Chair) Ms Melanie Leydin (Non-Executive Director) Dr Matthew Mesnik M.D. (Non- Executive Director) Mr Chris Ntoumenopoulos (Non- Executive Director) |
| Chief Executive Officer | Dr Tom Young M.D. (appointed 19 September 2022) |
| Company secretary | Mr Mathew Watkins |
| Registered office | Level 4, 100 Albert Road South Melbourne VIC 3205 Telephone: +61 3 9692 7222 Facsimile: +61 3 9077 9233 |
| Share register | Computershare Investor Services Pty Limited Level 3, 60 Carrington Street Sydney, NSW, 2000 Telephone: 1300 850 505 |
| Auditor | William Buck (Qld) Level 22, 307 Queen Street Brisbane QLD 4000 Telephone: +61 7 3229 5100 Facsimile: +61 7 3221 6027 |
| Legal advisors | Gadens Level 25 Bourke Place, 600 Bourke Street Melbourne VIC 3000 Telephone: +61 3 9252 2555 Facsimile: +61 3 9252 2500 |
| Bankers | Westpac Banking Corporation |
| Stock exchange listing | Medibio Limited securities are listed on the Australian Securities Exchange (ASX code: MEB & MEBOC) |
| Website | www.medibio.com.au |

Medibio Limited
Contents
31 December 2022

| | |
|---|----|
| Directors' report | 3 |
| Auditor's independence declaration | 5 |
| Statement of profit or loss and other comprehensive income | 6 |
| Statement of financial position | 7 |
| Statement of changes in equity | 8 |
| Statement of cash flows | 9 |
| Notes to the financial statements | 10 |
| Directors' declaration | 15 |
| Independent auditor's review report to the members of Medibio Limited | 16 |

Medibio Limited
Directors' report
31 December 2022

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'group' or 'consolidated entity') consisting of Medibio Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2022.

Directors

The following persons were directors of Medibio Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Mr David Trimboli (Non- Executive Director - appointed 25 August 2022) & (Non-Executive Chair - appointed 26 October 2022)

Ms Melanie Leydin (Non-Executive Director)

Mr Stephen Mitchley (Non-Executive Director - resigned 11 November 2022)

Dr Matt Mesnik (Non- Executive Director)

Mr Chris Ntoumenopoulos (Non- Executive Director - appointed 15 February 2023)

Principal activities

The principal activity of the Group is conducting clinical research, product development and early stage commercialisation of a mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions.

Review of operations

The loss for the group after providing for income tax amounted to \$420,700 (31 December 2021: \$644,694).

The loss for the period reflected substantially the continuing development of the Sleep Analysis of Major Depressive Episode (SAMDE) Clinical Study; the development of its sleep staging software, STAGER; the re-development of the Company's consumer app, LUCA and the commercialization of its corporate wellness product, ilumen.

The SAMDE enrolment is currently taking place across 12 centres across the US and is on schedule with 155 useable subjects, targeting a total of 300 useable. Phase 2 of the SAMDE enrolment is on track to begin by 15 March 2023 and will include clinical administered subjects initially totaling 100 subjects.

The MEB-001 algorithm continues to be enhanced and results continue to improve. The clinical team is analyzing more data regarding the clinical markers including opioid use disorder. The algorithm will continue to be enhanced with the addition of new data points derived from the several hundred new subjects.

The protocol design using the MINI 7.0.2 and PHQ-9 is being maintained. The study is being augmented now with a Breakthrough Device Designation (BDD) submission in advance of the ongoing submission and expanded clinician data collection subjects.

The Clinical development team continues to work to complete the updates to the clinical app (formerly LUCA) and is working with Elizabeth Lombardo PhD interacting her work on stress and anxiety. The new application will integrate the ability to collect biometric data, provide therapeutic interventions for stress, anxiety and insomnia and integrate fully into behavioral product platforms. The new APP is being developed to be used as a direct to consumer application as well as a clinician version which can be integrated into other mental health applications.

Corporate and Financial Update

Grant Opportunity – “Prediction of major depressive episodes from sleep data”

Medibio Ltd. and OnTime Trials, Inc. (OTT) are co applicants for a Small Business Innovation Research grant responsive to Funding Opportunity Announcement (FOA) Number PA-22-177PHS 2022-2 Has a total value over 2 years of \$1.8M US The Grant award date is May of 2023.

Grant Opportunity – “Sleep and circadian based mechanisms influencing the trajectory of OUD outcomes”

Medibio Ltd. Intends to apply for a research project grant responsive to FOA Number RFA-DA-23-059 , HEAL Initiative has a total value of \$3.0M over 4 years. The grant is to be awarded in August of 2023.

Medibio Limited
Directors' report
31 December 2022

Significant changes in the state of affairs

On 21 July 2022, the Consolidated Entity announced Sleep Analysis of Depressive Burden Study Clinical Trial Commencement. The study's goal is to re-train the algorithm based on the additional primary endpoint (MINI) and test algorithm performance for sensitivity, specificity, and negative and positive predictive values; and algorithm lockdown will take place after the FDA pre-submission meeting upon completion of the study, expected to be completed in 15-16 weeks from commencement.

On 25 August 2022, the Consolidated Entity appointed Mr. David Trimboli on Medibio's Board of Directors as Non-Executive Director with immediate effect

On 25 August 2022, the Consolidated Entity completed the Placement Tranche 2 by issuing 564,103,677 fully paid ordinary shares at an issue price of 0.0015 (1.5 cents) per share and 923,603,671 free attaching Options with exercise price at \$ 0.004 (0.4 cents) per New Option expiring on 15 June 2027. On the same date, the Group issued 27,708,110 unlisted options with exercise price at \$0.004 (0.4 cents) per Option expiring on 15 June 2027 for services provided by CPS of the Group's Capital Raising.

On 19 September 2022, the Consolidated Entity appointed Dr. Thomas R. Young M.D. as the Company's Chief Executive Officer, with immediate effect.

There were no other significant changes in the state of affairs of the group during the financial half-year.

Matters subsequent to the end of the financial half-year

On 15 February 2023, the Consolidated Entity appointed Mr. Christopher Ntoumernopoulos to Medibio's Board of Directors as Non-Executive Director with immediate effect.

On 15 February 2023, the Consolidated Entity announced a Capital Raising which would raise up to \$2.75 million (before costs) by way of a \$1.245 million Professional and Sophisticated investors by way of a Placement followed by a Share Purchase Plan, which is partially underwritten by the Directors to raise up to a further \$1.5 million. The Placement was subsequently completed on 21 February 2023 following the issue of 830,000,000 fully paid ordinary shares at an issue price of \$0.0015 (0.15 cents) per share.

No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the group's operations, the results of those operations, or the group's state of affairs in future financial years.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



David Trimboli
Non-Executive Chair

24 February 2023

The Directors
Medibio Limited
Level 4 100 Albert Road
South Melbourne VIC 3205

Auditor's Independence Declaration

As lead auditor for the review of Medibio Limited for the half-year ended 31 December 2022, I declare that, to the best of my knowledge and belief, there have been:

- (a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (b) no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Medibio Limited and the entities it controlled during the period.

William Buck

William Buck (Qld)
ABN 21 559 713 106

M. Monaghan

M J Monaghan
Director

Brisbane 24 February 2023

Medibio Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2022

| | | Consolidated | |
|--|-------------|-------------------------|-------------------------|
| | Note | 31 December 2022 | 31 December 2021 |
| | | \$ | \$ |
| Revenue | | | |
| Sales | 4 | 21,781 | 13,376 |
| Other income | 5 | 939,244 | 965,543 |
| Expenses | | | |
| Cost of sales | | (159) | (165,491) |
| Employee costs | | (320,834) | (282,494) |
| Research & development | | (216,928) | (143,606) |
| Finance costs | | (10,815) | (3,069) |
| Depreciation and amortisation expense | | (266,569) | (262,569) |
| Other expenses | | (566,420) | (766,384) |
| Loss before income tax expense | | (420,700) | (644,694) |
| Income tax expense | | - | - |
| Loss after income tax expense for the half-year attributable to the owners of Medibio Limited | | (420,700) | (644,694) |
| Other comprehensive income/(loss) | | | |
| <i>Items that may be reclassified subsequently to profit or loss</i> | | | |
| Foreign currency translation | | (70,021) | 24,588 |
| Other comprehensive income/(loss) for the half-year, net of tax | | (70,021) | 24,588 |
| Total comprehensive loss for the half-year attributable to the owners of Medibio Limited | | (490,721) | (620,106) |
| | | Cents | Cents |
| Basic earnings per share | 10 | (0.01) | (0.04) |
| Diluted earnings per share | 10 | (0.01) | (0.04) |

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Medibio Limited
Statement of financial position
As at 31 December 2022

| | Consolidated | |
|----------------------------------|---------------------|---------------------|
| | 31 December | 30 June 2022 |
| Note | 2022 | 2022 |
| | \$ | \$ |
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | 317,906 | 1,032,566 |
| Other current assets | 81,214 | 167,237 |
| Total current assets | <u>399,120</u> | <u>1,199,803</u> |
| Non-current assets | | |
| Other assets | 14,878 | 14,632 |
| Right-of-use assets | 22,529 | 65,406 |
| Intangibles | 6 7,935,853 | 7,207,859 |
| Total non-current assets | <u>7,973,260</u> | <u>7,287,897</u> |
| Total assets | <u>8,372,380</u> | <u>8,487,700</u> |
| Liabilities | | |
| Current liabilities | | |
| Trade and other payables | 719,911 | 1,001,272 |
| Lease liabilities | 22,148 | 66,419 |
| Employee liabilities | 146,759 | 238,961 |
| Other liabilities | 46,439 | 75,179 |
| Total current liabilities | <u>935,257</u> | <u>1,381,831</u> |
| Total liabilities | <u>935,257</u> | <u>1,381,831</u> |
| Net assets | <u>7,437,123</u> | <u>7,105,869</u> |
| Equity | | |
| Issued capital | 7 100,226,845 | 99,446,432 |
| Reserves | 6,216,317 | 6,244,776 |
| Accumulated losses | (99,006,039) | (98,585,339) |
| Total equity | <u>7,437,123</u> | <u>7,105,869</u> |

The above statement of financial position should be read in conjunction with the accompanying notes

Medibio Limited
Statement of changes in equity
For the half-year ended 31 December 2022

| Consolidated | Issued capital \$ | Foreign Currency Translation Reserve \$ | Share Based Payments Reserve \$ | Accumulated Losses \$ | Total equity \$ |
|--|----------------------------------|--|--|--------------------------------------|----------------------------|
| Balance at 1 July 2021 | 96,066,735 | (13,277) | 6,231,971 | (85,869,532) | 16,415,897 |
| Loss after income tax expense for the half-year | - | - | - | (644,694) | (644,694) |
| Other comprehensive income for the half-year, net of tax | - | 24,588 | - | - | 24,588 |
| Total comprehensive income/(loss) for the half- year | - | 24,588 | - | (644,694) | (620,106) |
| <i>Transactions with owners in their capacity as owners:</i> | | | | | |
| Contributions of equity, net of transaction costs | 1,278,250 | - | - | - | 1,278,250 |
| Share-based payments | - | - | (36,334) | - | (36,334) |
| Balance at 31 December 2021 | <u>97,344,985</u> | <u>11,311</u> | <u>6,195,637</u> | <u>(86,514,226)</u> | <u>17,037,707</u> |

| Consolidated | Issued capital \$ | Foreign Currency Translation Reserve \$ | Share Based Payments Reserve \$ | Accumulated Losses \$ | Total equity \$ |
|--|----------------------------------|--|--|--------------------------------------|----------------------------|
| Balance at 1 July 2022 | 99,446,432 | 45,726 | 6,199,050 | (98,585,339) | 7,105,869 |
| Loss after income tax expense for the half-year | - | - | - | (420,700) | (420,700) |
| Other comprehensive loss for the half-year, net of tax | - | (70,021) | - | - | (70,021) |
| Total comprehensive loss for the half-year | - | (70,021) | - | (420,700) | (490,721) |
| <i>Transactions with owners in their capacity as owners:</i> | | | | | |
| Contributions of equity, net of transaction costs (note 7) | 780,413 | - | - | - | 780,413 |
| Share-based payments | - | - | 41,562 | - | 41,562 |
| Balance at 31 December 2022 | <u>100,226,845</u> | <u>(24,295)</u> | <u>6,240,612</u> | <u>(99,006,039)</u> | <u>7,437,123</u> |

The above statement of changes in equity should be read in conjunction with the accompanying notes

Medibio Limited
Statement of cash flows
For the half-year ended 31 December 2022

| | Consolidated | |
|---|-------------------------|-------------------------|
| | 31 December 2022 | 31 December 2021 |
| Note | \$ | \$ |
| Cash flows from operating activities | | |
| Receipts from customers | 21,781 | 32,332 |
| R&D Grants and other income | 938,377 | 965,540 |
| Payments to suppliers and employees | <u>(1,430,342)</u> | <u>(1,163,579)</u> |
| Net cash used in operating activities | <u>(470,184)</u> | <u>(165,707)</u> |
| Cash flows from investing activities | | |
| Purchase of intangible assets | (949,763) | (1,876,768) |
| Interest received | 867 | 3 |
| Net cash used in investing activities | <u>(948,896)</u> | <u>(1,876,765)</u> |
| Cash flows from financing activities | | |
| Proceeds from issue of shares | 7 846,156 | 1,300,000 |
| Share issue transaction costs | (65,743) | (78,000) |
| Repayment of lease liabilities | <u>(44,271)</u> | <u>(44,953)</u> |
| Net cash from financing activities | <u>736,142</u> | <u>1,177,047</u> |
| Net decrease in cash and cash equivalents | (682,938) | (865,425) |
| Cash and cash equivalents at the beginning of the financial half-year | 1,032,566 | 2,311,551 |
| Effects of exchange rate changes on cash and cash equivalents | <u>(31,722)</u> | <u>(1,967)</u> |
| Cash and cash equivalents at the end of the financial half-year | <u><u>317,906</u></u> | <u><u>1,444,159</u></u> |

The above statement of cash flows should be read in conjunction with the accompanying notes

Medibio Limited
Notes to the financial statements
31 December 2022

Note 1. General information

The financial statements cover Medibio Limited as a group consisting of Medibio Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Medibio Limited's functional and presentation currency.

Medibio Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Level 4, 100 Albert Road
South Melbourne VIC 3205
Telephone: +61 3 9692 7222
Facsimile: +61 3 9077 9233

A description of the nature of the group's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 24 February 2023.

Note 2. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. These standards did not have an impact on the group.

Going concern

As at 31 December 2022, the Group had a net asset position of \$7,437,123 (30 June 2022: \$7,105,859). However as at 31 December 2022 it had:

- Net current liability position of \$536,137 (30 June 2022: \$182,028)
- Incurred a comprehensive loss for the period of \$490,721 (31 December 2021: \$620,106)
- Net cash outflows from operations of -\$470,184(31 December 2021: \$165,707)
- Cash at bank of \$317,906 (30 June 2022: \$1,032,566)

These factors indicate a material uncertainty exists which may cast significant doubt as to whether the Group will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report.

Medibio Limited
Notes to the financial statements
31 December 2022

Note 2. Significant accounting policies (continued)

Although there are significant inherent risks and uncertainties in the Group's cashflow forecasts, management have concluded that given the historical ability to raise capital, founded on core shareholder support, and the development of the FDA pre-validation process and expected positive results upon its currently expected conclusion in July, the Group reasonably expects to be able to raise sufficient capital to complete the FDA validation and pre-commercialisation phase of its development.

On 15 February 2023, the Consolidated Entity announced a Capital Raising which would raise up to \$2.75 million (before costs) by way of a \$1.245 million Professional and Sophisticated investors by way of a Placement followed by a Share Purchase Plan, which is partially underwritten by the Directors to raise up to a further \$1.5 million. The Placement was subsequently completed on 21 February 2023 following the issue of 830,000,000 fully paid ordinary shares at an issue price of \$0.0015 (0.15 cents) per share.

Accordingly, despite the aforementioned significant material uncertainties, it is concluded that subject to the successful raising of funds expected in the forecast period, the Group will continue as a going concern for at least twelve months from the date of signing the financial statements and therefore, these financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or to the amounts and classification of liabilities that might be necessary should the Group not continue as a going concern.

Note 3. Operating segments

The consolidated entity has one operating segment, being the research, development and commercialisation of its Software as a Service product, and two geographical locations, being Australia and the United States. It maintains a US based subsidiary to support US and Canadian research and development activities.

All revenue earned during the half year's ended December 2022 and December 2021 were sourced from Australia.

All assets reside in two geographical regions being Australia \$7,657,688 (June 2022: \$7,584,164) and USA -\$220,565 (June 2022: -\$478,295)

Note 4. Sales

| | Consolidated | |
|-------|-------------------------|-------------------------|
| | 31 December 2022 | 31 December 2021 |
| | \$ | \$ |
| Sales | <u>21,781</u> | <u>13,376</u> |

Note 5. Other income

| | Consolidated | |
|------------------------------------|-------------------------|-------------------------|
| | 31 December 2022 | 31 December 2021 |
| | \$ | \$ |
| R&D grant/rebate, net of allowance | 938,377 | 864,813 |
| Government grants | - | 100,727 |
| Interest | 867 | 3 |
| | <u>939,244</u> | <u>965,543</u> |

Medibio Limited
Notes to the financial statements
31 December 2022

Note 6. Non-current assets - intangibles

| | Consolidated | |
|---|-------------------------|-------------------------|
| | 31 December | |
| | 2022 | 30 June 2022 |
| | \$ | \$ |
| Goodwill - at cost | 444,999 | 444,999 |
| Goodwill - Acquisition of Vital Conversations Pty Ltd | 309,100 | 309,100 |
| Goodwill - Accumulated impairment losses | <u>(754,099)</u> | <u>(754,099)</u> |
| | - | - |
| Development - at cost | 4,286,019 | 4,247,051 |
| Less: Impairment | <u>(2,241,972)</u> | <u>(2,241,972)</u> |
| | <u>2,044,047</u> | <u>2,005,079</u> |
| Luca Consumer app Development - at cost | 1,456,214 | 1,456,214 |
| Less: Accumulated amortisation | <u>(290,066)</u> | <u>(145,033)</u> |
| | <u>1,166,148</u> | <u>1,311,181</u> |
| ilumen Application Development - at cost | 750,772 | 750,772 |
| Less: Accumulated amortisation | <u>(377,044)</u> | <u>(300,308)</u> |
| | <u>373,728</u> | <u>450,464</u> |
| MEB-001 Application Development - at cost | <u>4,351,930</u> | <u>3,441,135</u> |
| Data files - at cost | 7,794,644 | 7,794,644 |
| Less: Impairment | <u>(7,794,644)</u> | <u>(7,794,644)</u> |
| | - | - |
| | <u><u>7,935,853</u></u> | <u><u>7,207,859</u></u> |

Medibio Limited
Notes to the financial statements
31 December 2022

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

| | Goodwill | Capitalised Developme nt Costs | Luca Consumer app | Illumen Application | MEB-001 Application | Data file | Total |
|------------------------------------|----------|--------------------------------------|-------------------------|------------------------|------------------------|-------------|------------------|
| Consolidated | \$ | \$ | \$ | \$ | \$ | \$ | \$ |
| Balance at 30 June 2021 | - | 4,381,065 | - | 600,618 | 1,908,974 | 7,794,644 | 14,685,301 |
| Additions | - | 1,322,200 | - | - | 1,532,161 | - | 2,854,361 |
| Impairment of assets | - | (2,241,972) | - | - | - | (7,794,644) | (10,036,616) |
| Transfers in/(out) | - | (1,456,214) | 1,456,214 | - | - | - | - |
| Amortisation expense | - | - | (145,033) | (150,154) | - | - | (295,187) |
| Balance at 30 June 2022 | - | 2,005,079 | 1,311,181 | 450,464 | 3,441,135 | - | 7,207,859 |
| Additions | - | 38,968 | - | - | 910,795 | - | 949,763 |
| Amortisation expense | - | - | (145,033) | (76,736) | - | - | (221,769) |
| Balance at 31 December 2022 | - | 2,044,047 | 1,166,148 | 373,728 | 4,351,930 | - | 7,935,853 |

Note 7. Equity - issued capital

| | Consolidated | | | |
|------------------------------|-----------------------------|----------------------|-----------------------------|---------------------|
| | 31 December 2022 | 30 June 2022 | 31 December 2022 | 30 June 2022 |
| | Shares | Shares | \$ | \$ |
| Ordinary shares - fully paid | <u>3,320,593,794</u> | <u>2,756,490,117</u> | <u>100,226,845</u> | <u>99,446,432</u> |

Movements in ordinary share capital

| Details | Date | Shares | Issue price | \$ |
|-------------------|-------------------------|-----------------------------|--------------------|---------------------------|
| Balance | 1 July 2022 | 2,756,490,117 | | 99,446,432 |
| Issue of shares | 25 August 2022 | 564,103,677 | \$0.0015 | 846,156 |
| Share Issue Costs | | - | | (65,743) |
| Balance | 31 December 2022 | <u>3,320,593,794</u> | | <u>100,226,845</u> |

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Medibio Limited
Notes to the financial statements
31 December 2022

Note 8. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 9. Events after the reporting period

On 15 February 2023, the Consolidated Entity appointed Mr.Christopher Ntoumernopoulos to Medibio's Board of Directors as Non-Executive Director with immediate effect.

On 15 February 2023, the Consolidated Entity announced a Capital Raising which would raise up to \$2.75 million (before costs) by way of a \$1.245 million Professional and Sophisticated investors by way of a Placement followed by a Share Purchase Plan, which is partially underwritten by the Directors to raise up to a further \$1.5 million. The Placement was subsequently completed on 21 February 2023 following the issue of 830,000,000 fully paid ordinary shares at an issue price of \$0.0015 (0.15 cents) per share.

No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the group's operations, the results of those operations, or the group's state of affairs in future financial years.

Note 10. Earnings per share

| | Consolidated | |
|---|-------------------------|-------------------------|
| | 31 December 2022 | 31 December 2021 |
| | \$ | \$ |
| Loss after income tax attributable to the owners of Medibio Limited | <u>(420,700)</u> | <u>(644,694)</u> |
| | Number | Number |
| Weighted average number of ordinary shares used in calculating basic earnings per share | <u>3,151,975,847</u> | <u>1,811,377,247</u> |
| Weighted average number of ordinary shares used in calculating diluted earnings per share | <u>3,151,975,847</u> | <u>1,811,377,247</u> |
| | Cents | Cents |
| Basic earnings per share | (0.01) | (0.04) |
| Diluted earnings per share | (0.01) | (0.04) |

Medibio Limited
Directors' declaration
31 December 2022

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the group's financial position as at 31 December 2022 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



David Trimboli
Non-Executive Chair

24 February 2023

Medibio Limited

Independent auditor's review report

Report on the Review of the Half-Year Financial Report

Conclusion

We have reviewed the accompanying half-year financial report of Medibio Limited (the company) and the entities it controlled at the half-year's end or from time to time during the half year (the consolidated entity), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Medibio Limited is not in accordance with the Corporations Act 2001 including:

- a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the half year ended on that date; and
- b) complying with Australian Accounting Standard 134 Interim Financial Reporting and the Corporations Regulations 2001.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the consolidated entity in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Material Uncertainty related to Going Concern

We draw attention to Note 2 in the financial report, which indicates that the consolidated entity incurred a comprehensive loss of \$490,721 (31 December 2021: \$620,106), had net cash outflows from operations of \$470,184 (31 December 2021: \$165,707) during the half year ended 31 December 2022. As stated in Note 2, these events or conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the consolidated entity's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Responsibility of Management for the Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Half-Year Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the consolidated entity's financial position as at 31 December 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

William Buck

William Buck (Qld)

ABN: 21 559 713 106

M. Monaghan

M J Monaghan

Brisbane 24 February 2023